Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
August 10, 2023 16:05 ET | Vor Biopharma
Next trem-cel clinical data update expected by year-end 2023VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiationSecured non-exclusive license to Cas9 gene-edited HSCs ...
Aptose Biosciences Inc. logo
Aptose Reports Results for the Second Quarter 2023
August 10, 2023 16:02 ET | Aptose Biosciences, Inc.
            ─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67%...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
August 01, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow...
AI in Context: How Quantexa Augments and Automates Decision Intelligence with AI
Quantexa Bringing Total Global Investment in Artificial Intelligence Research and Development to Over $250M by 2027
July 09, 2023 19:01 ET | Quantexa
Quantexa CEO outlines vision for investment in support of UK Government’s plan to make UK an AI Hub, which includes: Over $155M in new global investments aimed at accelerating enterprise...
logo-header-min.png
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
June 26, 2023 07:00 ET | Marker Therapeutics
HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) (Marker or the Company), a clinical-stage immuno-oncology company focusing on developing next-generation T...
Aptose Biosciences Inc. logo
Aptose Presents Highlights from Clinical Update
June 10, 2023 12:00 ET | Aptose Biosciences, Inc.
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat...
Vor-Wordmark-RGB-FullColor-070920.png
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
June 09, 2023 07:30 ET | Vor Biopharma
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust enrollment; additional data...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
June 05, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman...
Melissa-new-logo-no-tag-hi-res[2].jpg
Melissa Points to Real-Time Data Quality as Key to Compliance Initiatives in Online Gambling
May 31, 2023 08:00 ET | Melissa
RANCHO SANTA MARGARITA, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Melissa, a leading provider of global data quality, identity verification, and address management solutions, today cited clean data...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
May 11, 2023 16:05 ET | Vor Biopharma
VBP101 clinical data update planned at European Hematology Association (EHA) 2023VCAR33ALLO IND submission on-track for 1H 2023 CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:...